Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint
This article was originally published in The Pink Sheet Daily
FDA's draft guidance for clinical trials of drugs for hospital-acquired or ventilator-associated bacterial pneumonia is strict, even compared with the draft guidance for community-acquired bacterial pneumonia.
You may also be interested in...
Public/private working group’s “interim considerations” of how best to design clinical trials for VABP and hospital-acquired bacterial pneumonia would add symptom improvement to a mortality endpoint for the latter.
Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.
Clinical response data in Theravance’s nosocomial pneumonia studies are difficult to interpret because some patients died shortly after being deemed as cured, the agency says. However, FDA’s statistical reviewer concedes the problem may be a lack of specificity in the 28-day window for assessing mortality.